platelet aggregation

血小板凝集能

WordNet

1. tiny bits of protoplasm found in vertebrate blood; essential for blood clotting (同)blood_platelet, thrombocyte

PrepTutorEJDIC

1. 〈U〉集合 / 〈C〉集合体,集団

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/06/26 09:32:13」(JST)

wiki en

[Wiki en表示]

Platelets
Image from a light microscope (500 ×) from a Giemsa-stained peripheral blood smear showing platelets (blue) surrounded by red blood cells

Platelets, also called "thrombocytes", are blood cells whose function (along with the coagulation factors) is to stop bleeding. Platelets have no nucleus: they are fragments of cytoplasm which are derived from the megakaryocytes of the bone marrow, and then enter the circulation. These unactivated platelets are biconvex discoid structures shaped like a lens, 2–3 µm in greatest diameter. Platelets are found only in mammals, an adaptation that may have evolved to offset the risk of death from hemorrhage at childbirth – a risk unique to mammals.

On a stained blood smear, platelets appear as dark purple spots, about 20% the diameter of red blood cells. The smear is used to examine platelets for size, shape, qualitative number, and clumping. The ratio of platelets to red blood cells in a healthy adult is 1/10 to 1/20.

The main function of platelets is to contribute to hemostasis: the process of stopping bleeding at the site of interrupted endothelium. They gather at the site and unless the interruption is physically too large, they plug the hole. First, platelets attach to substances outside the interrupted endothelium: adhesion. Second, they change shape, turn on receptors and secrete chemical messengers: activation. Third, they connect to each other through receptor bridges: aggregation. Formation of this platelet plug (primary hemostasis) is associated with activation of the coagulation cascade with resultant fibrin deposition and linking (secondary hemostasis). These processes may overlap: the spectrum is from a predominantly platelet plug, or "white clot" to a predominantly fibrin clot, or "red clot" or the more typical mixture. The final result is the clot. Some would add the subsequent clot retraction and platelet inhibition as fourth and fifth steps to the completion of the process and still others a sixth step wound repair.

Low platelet concentration is thrombocytopenia and is due to either decreased production or increased destruction. Elevated platelet concentration is thrombocytosis and is either congenital, reactive (to cytokines), or due to unregulated production: one of the myeloprolerative neoplasms or certain other myeloid neoplasms. A disorder of platelet function is a thrombocytopathy.

Normal platelets can respond to an abnormality on the vessel wall rather than to hemorrhage, resulting in inappropriate platelet adhesion/activation and thrombosis:the formation of a clot within an intact vessel. These arise by different mechanisms than a normal clot. Examples are: extending the fibrin clot of venous thrombosis; extending an unstable or ruptured arterial plaque, causing arterial thrombosis; and microcirculatory thrombosis. An arterial thrombus may partially obstruct blood flow, causing downstream ischemia; or completely obstruct it, causing downstream infarction.

Discovery, early observations, and naming

George Gulliver in 1841 drew pictures of platelets using the twin lens (compound) microscope invented in 1830 by Joseph Jackson Lister. This microscope improved resolution sufficiently that it was possible to see platelets for the first time. William Addison in 1842 drew pictures of a platelet-fibrin clot. Lionel Beale in 1864 was the first to publish a drawing showing platelets. Max Schultze in 1865 described what he called "spherules", which he noted were much smaller than red blood cells, occasionally clumped, and were sometimes found in collections of fibrin material Giulio Bizzozero in 1882 studied the blood of amphibians microscopically in vivo.   He named Schultz's spherules (It.) piastrine: little plates. William Osler observed them and, in published lectures in 1886, called them a third corpuscle and a blood plaque and described them as a colorless protoplasmic disc. James Wright examined blood smears using the stain named for him, and used the term plates in his 1906 publication but changed to platelets in his 1910 publication which has become the universally accepted term.

The term thrombocyte (clot cell) arose in the early 1900s and is sometimes used as a synonym for platelet; but not generally in the scientific literature, except as a root word for other terms related to platelets. This is partly due to the discovery in non-mammalian vertebrates of nucleated cells that have a hemostatic function and were given the name thrombocyte.

In some contexts, the word thrombus is used interchangeably with the word clot, regardless of its composition (white, red, or mixed). In other contexts it is used to contrast a normal from an abnormal clot: thrombus arises from physiologic hemostasis, thrombosis arises from a pathologic and excessive quantity of clot. In a third context it is used to contrast the result from the process: thrombus is the result, thrombosis is the process.

Measurement

Platelet concentration is measured either manually using a hemacytometer, or by placing blood in an automated platelet analyzer using electrical impedance, such as a Coulter counter. The normal range (99% of population analyzed) for platelets in healthy Caucasians is 150,000 to 400,000 per cubic millimeter  (a mm³ equals a microliter). or 150–400 × 10⁹ per liter. The normal range has been confirmed to be the same in the elderly and Spanish populations. Men as a group have slightly higher mean values than women.

The platelet concentration is often referred to informally as the platelet count without stating the units.

Symptoms of platelet disorders

Spontaneous and excessive bleeding can occur because of platelet disorders. This bleeding can be caused by deficient numbers of platelets, dysfunctional platelets, or very excessive numbers of platelets: over 1.0 million/microliter. (The excessive numbers create a relative vonWillibrand factor deficiency due to sequestration).

One can get a clue as to whether bleeding is due to a platelet disorder or a coagulation factor disorder by the characteristics and location of the bleeding. All of the following suggest platelet bleeding, not coagulation bleeding: the bleeding from a skin cut such as a razor nick is prompt and excessive, but can be controlled by pressure; spontaneous bleeding into the skin which causes a purplish stain named by its size: petechiae, purpura, ecchymoses; bleeding into mucous membranes causing bleeding gums, nose bleed, and gastrointestinal bleeding; menorrhagia; and intraretinal and intracranial bleeding.

Excessive numbers of platelets, and/or normal platelets responding to abnormal vessel walls, can result in venous thrombosis and arterial thrombosis. The symptoms depend on the site of thrombosis.

Kinetics

Platelets derive from totipotent marrow stem cells

• Megakaryocyte and platelet production is regulated by thrombopoietin, a hormone produced in the kidneys and liver.
• Each megakaryocyte produces between 1,000 and 3,000 platelets during its lifetime.
• An average of 10¹¹ platelets are produced daily in a healthy adult.
• Reserve platelets are stored in the spleen, and are released when needed by splenic contraction induced by the sympathetic nervous system.

Platelets extruded from megakaryocytes

• The average life span of circulating platelets is 8 to 9 days. Life span of individual platelets is controlled by the internal apoptotic regulating pathway, which has a Bcl-x_L timer.
• Old platelets are destroyed by phagocytosis in the spleen and liver.

Dynamics

3D Rendering of Platelets

An overview summarizing platelet dynamics, the complex process of converting inactive platelets into a platelet plug, is essential^{EL 2}. Complicating any verbal description is the fact that at least 193 proteins an 301 interactions are involved in platelet dynamics. The separation of platelet dynamics into three stages is useful in this regard, but it is artificial: in fact, each stage is initiated in rapid succession, and each continues until the trigger for that stage is no longer present, so there is overlap.

Adhesion

Thrombus formation on an intact endothelium is prevented by nitric oxide, prostacyclin, and CD39.

Endothelial cells are attached to the subendothelial collagen by von Willebrand factor (vWF) which these cells produce. vWF is also stored in endothelial cells and secreted constitutively into the blood. Platelets store vWF in their granules.

When the endothelial layer is disrupted, collagen and vWF anchor platelets to the subendothelium. Platelet GP1b-IX-V receptor binds with vWF; and GPVI receptor binds with collagen.

Activation

Scanning electron micrograph of blood cells. From left to right: human erythrocyte, activated platelet, leukocyte.

An overview of platelet activation is a useful introduction to this multifaceted process. ^{[EL 3]}

Inhibition

The intact endothelial lining inhibits platelet activation by producing nitric oxide, endothelial-ADPase, and PGI₂.  Endothelial-ADPase degrades the platelet activator, ADP.

Trigger (Induction)

Platelet activation begins seconds after adhesion occurs. It is triggered when collagen from the subendothilium, and/or tissue factor from the media and adventitia bind with their respective receptors on the platelet. These are G protein coupled receptors and they turn on cAMP mediated signaling pathways within the platelet. Families of three G proteins (Gi, Gq, G12) operate together for full activation.

Components (Consequences)

Coagulation facilitation

One of the signaling pathways turns on scramblase, which moves negatively charged phospholipids from the inner to the outer platelet membrane surface. These phospholipids then bind the tenase and prothrombinase complexes, two of the sites of interplay between platelets and the coagulation cascade. Calcium ions are essential for the binding of these coagulation factors.

Morphology change

Mitochondrial hyperpolarization is a key event in initiating changes in morphology. Intraplatelet calcium concentration increases, stimulating the interplay between microtubule/actin filament complex. The continuous changes in shape from the unactivated to the fully activated platelet is best seen on scanning electron microscopy.^{[EL 4]} Three steps along this path are named early dendritic, early spread and spread. The surface of the unactivated platelet looks very similar to the surface of the brain, with a wrinkled appearance from numerous shallow folds to increase the surface area; early dendritic, an octopus with multiple arms and legs; early spread, an uncooked frying egg in a pan, the "yolk" being the central body; and the spread, a cooked fried egg with a denser central body. These changes are all brought about by the interaction of the microtubule/actin complex with the platelet cell membrane and open canalicular system (OCS), which is an extension and invagination of that membrane. This complex runs just beneath these membranes, and is the chemical motor which literally pulls the invaginated OCS out of the interior of the platelet like turning pants pockets inside out, creating the dendrites.^{[EL 7]} and then spreads each dendrite until the entire OCS becomes indistinguishable from the initial platelet membrane as it forms the "fried egg". This dramatic increase in surface area comes about with neither stretching nor adding phospholipids to the platelet membrane.

Granule secretion

Diagram of the structure of a platelet showing the granules

Platelets contain dense granules, lambda granules and alpha granules. Activated platelets secrete the contents of these granules through their canalicular systems to the exterior.  Granule characteristics:

• dense (or delta) granules (containing ADP or ATP, calcium, and serotonin)
• lambda granules – similar to lysosomes and contain several hydrolytic enzymes.
• Alpha granules (containing P-selectin, platelet factor 4, transforming growth factor-β1, platelet-derived growth factor, fibronectin, B-thromboglobulin, vWF, fibrinogen, and coagulation factors V and XIII).

GPIIb/IIIa activation

Thromboxane A₂ synthesis increases during activation: it is secreted and acts on both its own thromboxane receptors (the so-called "out-in" mechanism), and those of other platelets. These receptors trigger intraplatelet signaling, which converts GPIIb/IIIa receptors to their active form to initiate aggregation.

Aggregation

Platelet clumps in a blood smear

Aggregation begins minutes after activation, and occurs as a result of turning on the GPIIb/IIIa receptor, which allows these receptors to bind with vWF or fibrinogen. There are 50–100 of these receptors per platelet. When any one or more of at least nine different platelet surface receptors are turned on during activation, intraplatelet signaling pathways cause existing GpIIb/IIIa receptors to change shape – curled to straight – and thus become capable of binding.

Classically it was thought that this was the only mechanism involved in aggregation, but three new mechanisms have been identified which can initiate aggregation, depending on the velocity of blood flow (i.e. shear range).

Retraction

Inhibition of completed plug

Wound repair

Main article: Wound repair

The blood clot is only a temporary solution to stop bleeding; tissue repair is needed. Small interruptions in the endothelium are handled by physiological mechanisms; large interruptions by the trauma surgeon. The fibrin is slowly dissolved by the fibrinolytic enzyme, plasmin, and the platelets are cleared by phagocytosis.

Platelet-coagulation factor interactions

In addition to interacting with vWF and fibrin, platelets interact with thrombin, Factors X, Va, VIIa, XI, IX, and prothrombin to complete clot formation via the coagulation cascade. Six studies suggested platelets express tissue factor: the definitive study shows they do not.

Role in non-hematologic diseases

Coronary artery disease

Cerebrovascular disease

Diabetes mellitus

Inflammation

In addition to being the cellular effector of hemostasis, platelets are rapidly deployed to sites of injury or infection, and potentially modulate inflammatory processes by interacting with leukocytes and by secreting cytokines, chemokines, and other inflammatory mediators. Platelets also secrete platelet-derived growth factor (PDGF).

Antimicrobial function

Tumor growth and metastasis

Clot formation in non-mammalian vertebrates

Non-mammalian vertebrates instead of having platelets have thrombocytes which have a nucleus and resemble B lymphocytes in morphology. They aggregate in response to thrombin (but not to ADP, serotonin, nor adrenaline, as platelets do).

Tests of platelet function

Bleeding time

Developed by Duke in 1910 and bearing his name, it measured the time for bleeding to stop from a standardized wound in the ear lobe which is blotted each 30 seconds. Normal was less than 3 minutes. More modern techniques are now used. A normal bleeding time reflects sufficient platelet numbers and function plus normal microvasculature.

Platelet aggregation tests

Flow cytometry

Platelet disorders

Adapted from

The three broad categories of platelet disorders are "not enough"; "dysfunctional"; and "too many".

Thrombocytopenia

• Immune associated
• Immune thrombocytopenias (ITP) – formerly known as immune thrombocytopenia purpura and idiopathic thrombocytopenic purpura
• Onyalai
• Thrombotic thrombocytopenic purpura
• Drug-induced thrombocytopenic purpura (five known drugs – most problematic is heparin-induced thrombocytopenia (HIT)
• Gaucher's disease
• Pregnancy associated
• Neonatal alloimmune associated
• Aplastic anemia
• Transfusion associated
• Pseudothrombocytopenia

Thrombasthenias

• Congenital
• Acquired
  • HELLP syndrome
  • Hemolytic-uremic syndrome
  • Chemotherapy
  • Dengue
  • Disorders of adhesion
    • Bernard-Soulier syndrome
    • Paroxysmal nocturnal hemoglobinuria
    • Asthma
    • Aspirin-induced asthma|Samter’s Triad (Aspirin Exacerbated Respiratory Disease/AERD)
    • Cancer
    • Malaria
  • Disorders of activation
    • Disorders of granule amount or release
    • Hermansky-Pudlak Syndrome
    • Gray platelet syndrome
    • ADP Receptor defect
    • Decreased cyclooxygenase activity, induced or congenital
    • Storage pool defects, acquired or congenital
  • Disorders of aggregation
    • Glanzmann's thrombasthenia
    • Wiskott–Aldrich syndrome

Thrombocytosis and Thrombocythemia

• Congenital
• Reactive
• Myeloproliferative neoplasms – platelets are elevated and activated
  • Essential thrombocytosis
  • Polycythemia vera
• Associated with other myeloid neplasms

Drugs affecting platelets

Anti-inflammatory drugs

Some drugs used to treat inflammation have the unwanted side effect of suppressing normal platelet function. These are the non-steroidal anti-inflammatory drugs (NSAIDS). Aspirin irreversibly disrupts platelet function by inhibiting cyclooxygenase-1 (COX1), and hence normal hemostasis.  The resulting platelets are unable to produce new cyclooxygenase because they have no DNA.  Normal platelet function will not return until the use of aspirin has ceased and enough of the affected platelets have been replaced by new ones, which can take over a week.  Ibuprofen, another NSAID, does not have such a long duration effect, with platelet function usually returning within 24 hours, and taking ibuprofen before aspirin prevents the irreversible effects of aspirin. 

Uremia, a consequence of renal failure, leads to platelet dysfunction that may be ameliorated by the administration of desmopressin.

Drugs which suppress platelet function

These drugs are used to prevent thrombus formation.

Oral agents

• aspirin
• clopidogrel
• cilostazol
• ticlopidine
• ticagrelor
• prasugrel.

Drugs which stimulate platelet production

• Thrombopoietin mimetics
• Desmopressin
• Factor VIIa

Intravenous agents

• abciximab,
• eptifibatide
• tirofiban
• Others oprelvekin, romiplostim, eltrombopag.

Therapy with platelets

Transfusion

Indications

Platelet transfusion is most frequently used to correct unusually low platelet counts, either to prevent spontaneous bleeding (typically at counts below (10–15)×10⁹/L) or in anticipation of medical procedures that will necessarily involve some bleeding. For example, in patients undergoing surgery, a level below 50×10⁹/L is associated with abnormal surgical bleeding, and regional anaesthetic procedures such as epidurals are avoided for levels below 80×10⁹/L. Platelets may also be transfused when the platelet count is normal but the platelets are dysfunctional, such as when an individual is taking aspirin or clopidogrel. Finally, platelets may be transfused as part of a massive transfusion protocol, in which the three major blood components (red blood cells, plasma, and platelets) are transfused to address severe hemorrhage. Platelet transfusion is contraindicated in thrombotic thrombocytopenic purpura (TTP), as it fuels the coagulopathy.

Collection

Platelet concentrate.

Platelets are either isolated from collected units of whole blood and pooled to make a therapeutic dose, or collected by platelet apheresis: blood is taken from the donor, passed through a device which removes the platelets, and the remainder is returned to the donor in a closed loop. The industry standard is for platelets to be tested for bacteria before transfusion to avoid septic reactions, which can be fatal. Recently the AABB Industry Standards for Blood Banks and Transfusion Services (5.1.5.1) has allowed for use of pathogen reduction technology as an alternative to bacterial screenings in platelets.

Pooled whole-blood platelets, sometimes called “random” platelets, are separated by one of two methods. In the US, a unit of whole blood is placed into a large centrifuge in what is referred to as a “soft spin.” At these settings, the platelets remain suspended in the plasma. The platelet-rich plasma (PRP) is removed from the red cells, then centrifuged at a faster setting to harvest the platelets from the plasma. In other regions of the world, the unit of whole blood is centrifuged using settings that cause the platelets to become suspended in the “buffy coat” layer, which includes the platelets and the white blood cells. The “buffy coat” is isolated in a sterile bag, suspended in a small amount of red blood cells and plasma, then centrifuged again to separate the platelets and plasma from the red and white blood cells. Regardless of the initial method of preparation, multiple donations may be combined into one container using a sterile connection device to manufacture a single product with the desired therapeutic dose.

Apheresis platelets are collected using a mechanical device that draws blood from the donor and centrifuges the collected blood to separate out the platelets and other components to be collected. The remaining blood is returned to the donor. The advantage to this method is that a single donation provides at least one therapeutic dose, as opposed to the multiple donations for whole-blood platelets. This means that a recipient is not exposed to as many different donors and has less risk of transfusion-transmitted disease and other complications. Sometimes a person such as a cancer patient who requires routine transfusions of platelets will receive repeated donations from a specific donor to further minimize the risk. Pathogen reduction of platelets using for example, riboflavin and UV light treatments can also be carried out to reduce the infectious load of pathogens contained in donated blood products, thereby reducing the risk of transmission of transfusion transmitted diseases. In addition, apheresis platelets tend to contain fewer contaminating red blood cells because the collection method is more efficient than “soft spin” centrifugation at isolating the desired blood component.

Storage

Platelets collected by either method have a very short shelf life, typically five days. This results in frequent problems with short supply, as testing the donations often requires up to a full day. Since there are no effective preservative solutions for platelets, they lose potency quickly and are best when fresh.

Platelets are stored under constant agitation at 20–24 °C (68–75.2 °F). Storage at room temperature provides an environment where any bacteria that are introduced to the blood component during the collection process may proliferate and subsequently cause bacteremia in the patient. Regulations are in place in the United States that require products to be tested for the presence of bacterial contamination before transfusion.

Delivery to recipients

Platelets do not need to belong to the same A-B-O blood group as the recipient or be cross-matched to ensure immune compatibility between donor and recipient unless they contain a significant amount of red blood cells (RBCs). The presence of RBCs imparts a reddish-orange color to the product, and is usually associated with whole-blood platelets. An effort is sometimes made to issue type specific platelets, but this is not critical as it is with RBCs.

Prior to issuing platelets to the recipient, they may be irradiated to prevent transfusion-associated graft versus host disease or they may be washed to remove the plasma if indicated.

The change in the recipient's platelet count after transfusion is termed the "increment" and is calculated by subtracting the pre-transfusion platelet count from the post-transfusion platelet count. Many factors affect the increment including the recipient's body size, the number of platelets transfused, and clinical features that may cause premature destruction of the transfused platelets. When recipients fail to demonstrate an adequate post-transfusion increment, this is termed platelet transfusion refractoriness.

Platelets, either apheresis-derived or random-donor, can be processed through a volume reduction process. In this process, the platelets are spun in a centrifuge and the excess plasma is removed, leaving 10 to 100 mL of platelet concentrate. Such volume-reduced platelets are normally transfused only to neonatal and pediatric patients, when a large volume of plasma could overload the child's small circulatory system. The lower volume of plasma also reduces the chances of an adverse transfusion reaction to plasma proteins. Volume reduced platelets have a shelf life of only four hours.

Wound therapy

Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the deposition of extracellular matrix; fibroblast growth factor, insulin-like growth factor 1, platelet-derived epidermal growth factor, and vascular endothelial growth factor. Local application of these factors in increased concentrations through Platelet-rich plasma (PRP) is used as an adjunct in wound healing.

References

External links

1. Michelson, Alan D. (2013). Platelets (3rd ed.). Academic. ISBN 0-12-387837-3.  – 1351 pages; 60,000 references. Excerpts free online.

2. Video summarizing platelet dynamics ( Page will play audio when loaded)

3. Diagram of factors involved in platelet activation

4. Colorized scanning electron microscope image of unactivated and several activated platelets

5. Diagram of 5-HT stimulated signaling in platelet activation. [1]

6. Diagram of GPIIb/IIIa crossbridging by fibrin

7. Drawing of dendritic phase of platelet activation

8. Interaction of platelets with coagulation factors

9. Platelet function defects: 21 page review with diagrams

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 血小板機能検査 platelet function testing
• 2. 先天性および後天性血小板機能障害 congenital and acquired disorders of platelet function
• 3. 止血の概要 overview of hemostasis
• 4. 血小板生物学 platelet biology
• 5. アスピリンの無効および耐性 nonresponse and resistance to aspirin

English Journal

• In vitro inhibition of platelet aggregation by peptides derived from oat (Avena sativa L.), highland barley (Hordeum vulgare Linn. var. nudum Hook. f.), and buckwheat (Fagopyrum esculentum Moench) proteins.

• Yu G1, Wang F1, Zhang B1, Fan J2.
• Food chemistry.Food Chem.2016 Mar 1;194:577-86. doi: 10.1016/j.foodchem.2015.08.058. Epub 2015 Aug 19.
• Bioactive compounds present in foods could have beneficial effects on human health. In this study, we report the capacity of peptides released from oat, highland barley, and buckwheat proteins after enzymatic digestion to inhibit platelet aggregation in vitro. All hydrolysates showed high antiplatel
• PMID 26471595

• Rutin improves endotoxin-induced acute lung injury via inhibition of iNOS and VCAM-1 expression.

• Huang YC1, Horng CT2,3, Chen ST4, Lee SS5, Yang ML6, Lee CY7,8, Kuo WH9,10, Yeh CH11,12, Kuan YH7,8.
• Environmental toxicology.Environ Toxicol.2016 Feb;31(2):185-91. doi: 10.1002/tox.22033. Epub 2014 Aug 1.
• Endotoxins exist anywhere including in water pools, dust, humidifier systems, and machining fluids. The major causal factor is endotoxins in many serious diseases, such as fever, sepsis, multi-organ failure, meningococcemia, and severe morbidities like neurologic disability, or hearing loss. Endotox
• PMID 25080890

• Notoginsenoside Ft1 Promotes Fibroblast Proliferation via PI3K/Akt/mTOR Signaling Pathway and Benefits Wound Healing in Genetically Diabetic Mice.

• Zhang E1, Gao B1, Yang L1, Wu X2, Wang Z2.
• The Journal of pharmacology and experimental therapeutics.J Pharmacol Exp Ther.2016 Feb;356(2):324-32. doi: 10.1124/jpet.115.229369. Epub 2015 Nov 13.
• Wound healing requires the essential participation of fibroblasts, which is impaired in diabetic foot ulcers (DFU). Notoginsenoside Ft1 (Ft1), a saponin from Panax notoginseng, can enhance platelet aggregation by activating signaling network mediated through P2Y12 and induce proliferation, migration
• PMID 26567319

Japanese Journal

• A randomized, quadruple crossover single-blind study on immediate action of chewed and unchewed low-dose acetylsalicylic acid tablets in healthy volunteers

• Sai Yoshimichi,Kusaka Akiyo,Imanishi Kaori,Matsumoto Manami,Takahashi Rie,Sugimoto Natsumi,Sugama Junko,Anada Takako,Asakura Hidesaku,Miyamoto KenIchi
• Journal of Pharmaceutical Sciences 100(9), 3884-3891, 2011-09
• … A significant decrease in serum thromboxane B2 was observed 20 min after ingestion of chewed ECA, or intact or chewed NBA, and inhibition of platelet aggregation was also observed within 20 min. Thus, chewing of the ECA appears to result in a similar timing of ASA action to that in the case of chewed or unchewed NBA. …
• NAID 120003141589

• ラットにおける血液流動性と活性酸素動態に対する漢方薬の影響

• 石川 慎太郎,久保 哲也,砂川 正隆,俵積田 ゆかり,佐藤 孝雄,石野 尚吾,久光 正
• 日本東洋醫學雜誌 = Japanese journal of oriental medicine 62(3), 337-346, 2011-05-20
• 瘀血の状態では，血液が鬱滞することから腫脹や疼痛などの障害が現れる。瘀血は循環障害と捉えられ，血管抵抗性と血液流動性の側面から研究されてきた。血液流動性の変動要因には血球および血漿成分があり，その変動に活性酸素が深く関わっていると考えられている。今回，ラットに漢方薬（当帰芍薬散，柴胡加竜骨牡蛎湯，桃核承気湯，桂枝茯苓丸，十全大補湯）を投与して活性酸素動態と血液流動性への …
• NAID 10029129535

• 血小板2次凝集欠如および von Willebrand 病 type 2A を伴った本態性血小板血症の1男児例

• 庄司 朋子,長江 千愛,山下 敦己,武藤 真二,浅原 美恵子,木下 明俊,瀧 正志
• 日本小児血液学会雑誌 25(2), 102-106, 2011-04-30
• NAID 10029312197

Related Links

• platelet aggregation - definition of platelet aggregation in the ...

Definition of platelet aggregation in the Medical Dictionary. platelet aggregation explanation. Information about platelet aggregation in Free online English dictionary. What is platelet aggregation? Meaning of platelet aggregation ...

• Advanced Modular System for Platelet Aggregation Ristocetin ...

The AggRAM, for platelet aggregation and ristocetin cofactor testing offers unsurpassed precision, ease of use and flexibility. AggRAM couples four-channel laser optic modules with a powerful Windows interface. Up to two modules ...

Related Pictures

---

★リンクテーブル★

リンク元	「血小板凝集能」「血小板凝集」
拡張検索	「platelet aggregation inhibitor」
関連記事	「aggregation」

「血小板凝集能」

　　[★]

英

platelet aggregation

関

血小板、血小板凝集

「血小板凝集」

　　[★]

英

platelet aggregation

関

血小板粘着

「platelet aggregation inhibitor」

　　[★]

• 血小板凝集抑制薬、血小板凝集抑制剤、血小板凝集阻害薬、血小板凝集阻害剤

関

antiplatelet agent、antiplatelet drug、platelet antagonist、platelet inhibitor

「aggregation」

　　[★]

• n.

• 凝集、(細胞や受容体の)集合

関

agglutinate、agglutination、aggregate、assemblage、assemble、assembly、clump、come together、convergence、populate、population